Last Updated: June 2026
Published by: Orio Pharma — a specialist oncology medicine supplier serving patients, pharmacies, and distributors worldwide.
Medical Review: Reviewed by Dr. Farhan Hossain, MBBS, MD (Oncology)
Content Basis: This article is based on official prescribing information, product monographs, and regulatory product documentation from the FDA, EMA, and DGDA (Directorate General of Drug Administration, Bangladesh).
Sources: accessdata.fda.gov, accessdata.fda.gov, accessdata.fda.gov, accessdata.fda.gov, go.drugbank.com
Key Takeaways
- Letrozole (available as Lenor) is a nonsteroidal aromatase inhibitor approved for hormone receptor positive breast cancer in postmenopausal women, working by blocking the conversion of androgens to estrogens to reduce circulating estrogen levels.
- Lenor carries approval across three clinical settings: adjuvant treatment of early breast cancer, extended adjuvant therapy following prior tamoxifen use, and first- and second-line treatment of advanced breast cancer.
- The product is available exclusively as a 2.5 mg oral tablet, which may be taken without regard to meals, supporting flexible integration into both inpatient and outpatient oncology protocols.
- Commonly reported side effects include hot flashes, arthralgia, bone pain, hypercholesterolemia, nausea, and alopecia; somnolence and fatigue have also been reported and warrant ongoing clinical monitoring.
- Pre-treatment pregnancy testing, bone density monitoring, and serum cholesterol surveillance are key precautions that oncology institutions should build into patient management protocols.
- Lenor is manufactured by Eskayef Pharmaceuticals Ltd in Bangladesh and is available through our supply network for qualified hospital pharmacies, oncology centers, and licensed distributors in the Kingdom of Saudi Arabia.
What Is Letrozole and How Does It Work?
Letrozole is a nonsteroidal aromatase inhibitor indicated for the treatment of hormone receptor positive breast cancer in postmenopausal women. Available in the Saudi Arabian market under the brand name Lenor, letrozole belongs to the therapeutic class of Hormones / Antiestrogens / Aromatase Inhibitors and is a well-established option within oncology formularies.
Its mechanism of action centers on competitive inhibition of the aromatase enzyme system — the biological pathway responsible for converting androgens into estrogens. In postmenopausal women, peripheral aromatization is the primary source of circulating estrogen, so blocking this conversion significantly reduces systemic estrogen levels, depriving hormone-sensitive tumor cells of the hormonal stimulus that drives their proliferation.
This targeted endocrine mechanism makes letrozole particularly relevant in the management of hormone receptor positive breast cancer, where estrogen plays a direct role in disease progression. For B2B pharmaceutical buyers and hospital procurement teams in the Kingdom of Saudi Arabia, understanding this mechanism is essential when evaluating letrozole’s clinical positioning within oncology treatment protocols. 2.5 mg tablets are the available formulation for this indication.
Approved Indications for Letrozole
Letrozole carries regulatory approval across three distinct clinical indications, all within the postmenopausal breast cancer setting. Procurement professionals and formulary committees should note the following approved uses when evaluating Lenor for oncology department inclusion:
- Adjuvant treatment of early breast cancer: Letrozole is approved for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer, positioning it as a primary endocrine therapy option following surgical intervention in eligible patients.
- Extended adjuvant therapy after tamoxifen: Letrozole is also approved for extended adjuvant treatment in postmenopausal women with early breast cancer who have previously completed standard adjuvant tamoxifen therapy, addressing residual recurrence risk once tamoxifen treatment ends.
- First- and second-line advanced breast cancer: For postmenopausal women with hormone receptor positive or hormone receptor unknown advanced breast cancer, letrozole is FDA-approved as a first-line treatment option. This dual-line approval reflects its clinical utility across different stages of disease progression.
All letrozole prescribing decisions, including indication-specific selection, should be made by the treating physician in accordance with the official prescribing information and applicable clinical guidelines. Procurement inquiries regarding Lenor availability for these indications are welcomed from qualified institutional buyers.
Letrozole 2.5 mg Tablet: Available Strength and Form
Letrozole is available as a 2.5 mg oral tablet — the sole formulation offered under the Lenor brand for the Saudi Arabian market. The tablet is taken orally and may be administered without regard to meals, offering flexibility across clinical settings.
From a physicochemical standpoint, letrozole is characterized as a white to yellowish crystalline powder with the molecular formula C₁₇H₁₁N₅ and a molecular weight of 285.31. These properties are relevant for pharmaceutical storage and handling assessments within hospital pharmacy and distribution environments.
The oral tablet format supports straightforward integration into oncology treatment protocols across inpatient and outpatient settings. Specific dosing regimens and any required dose modifications are determined exclusively by the treating physician in accordance with the official prescribing information. Procurement teams should reference the product’s formulation details when completing formulary documentation or tender submissions for oncology departments in the Kingdom of Saudi Arabia.
Common and Serious Side Effects
Clinical teams and formulary reviewers evaluating letrozole 2.5 mg should be familiar with its established side effect profile, as documented in the official prescribing information. This information supports pharmacovigilance planning and patient management protocols within oncology departments.
Commonly reported side effects include:
- Hot flashes, flushing, and increased sweating
- Arthralgia and bone pain
- Asthenia and edema
- Headache and dizziness
- Hypercholesterolemia
- Nausea, constipation, diarrhea, vomiting, and abdominal pain
- Decreased appetite
- Insomnia and breast pain
- Dyspnea and coughing
- Alopecia
Effects warranting closer clinical monitoring include somnolence and fatigue, alongside the hypercholesterolemia noted above — elevated cholesterol levels in particular call for ongoing laboratory surveillance during the course of therapy.
Healthcare institutions incorporating letrozole into their formularies should ensure that oncology nursing and pharmacy teams are equipped to monitor for these effects and implement appropriate management pathways. The side effect profile is consistent with the drug’s mechanism of estrogen suppression and its systemic endocrine consequences. For a broader perspective on oncology pharmacotherapy, see our resource on understanding the role of targeted therapy in cancer treatment.
Warnings, Precautions, and Monitoring
Institutional pharmacists and oncology procurement teams should be aware of the key clinical precautions associated with letrozole therapy when preparing formulary submissions or clinical governance documentation.
Pregnancy testing: Although letrozole is indicated exclusively for postmenopausal women, pregnancy testing in females of reproductive potential is required prior to initiating therapy. This precaution should be built into pre-treatment screening protocols.
Bone density monitoring: Long-term estrogen suppression carries implications for skeletal health. Bone density monitoring should be considered during the course of letrozole therapy, with clinical teams establishing appropriate baseline and follow-up assessment schedules.
Serum cholesterol monitoring: Given the risk of hypercholesterolemia, serum cholesterol levels should be monitored during treatment. Institutions should ensure that lipid monitoring is integrated into routine oncology follow-up pathways.
Machinery and driving safety: Fatigue, dizziness, and somnolence have been reported with letrozole use. Patients should be advised to exercise caution when operating machinery or driving until their individual response to therapy is established.
Lactation: Lactation guidance is not applicable, as letrozole is indicated solely for postmenopausal women.
Regulatory Status and Market Context
Letrozole received for the treatment of breast cancer, making it one of the longer-standing aromatase inhibitors in global oncology practice. Its long regulatory track record — including international recognition of the originator product marketed as Femara — has supported its adoption across clinical guidelines and formularies worldwide.
In the Kingdom of Saudi Arabia, imported pharmaceutical products are subject to oversight by the Saudi Food and Drug Authority (SFDA). Oncology medicines, including aromatase inhibitors, must meet SFDA registration and importation requirements before distribution within the Kingdom. Institutional buyers and hospital procurement departments should verify current SFDA registration status for any letrozole product being considered for formulary inclusion.
Letrozole’s established international regulatory record supports its credibility as a procurement choice for oncology departments seeking evidence-based endocrine therapy options. B2B distributors operating in the KSA market should ensure full compliance with applicable SFDA importation and documentation requirements.
Sourcing Lenor (Letrozole) for the Saudi Arabian Market
For pharmaceutical buyers, hospital procurement officers, and oncology distributors operating in the Kingdom of Saudi Arabia, Lenor (Eskayef Pharmaceuticals Ltd) is the Bangladeshi-manufactured letrozole brand available through our supply network. Eskayef Pharmaceuticals Ltd is a recognized pharmaceutical manufacturer based in Bangladesh, and Lenor is produced in accordance with the company’s manufacturing standards.
Lenor 2.5 mg tablets are suitable for inclusion in:
- Hospital formularies — particularly oncology and endocrinology departments managing postmenopausal breast cancer patients
- Oncology treatment centers — both public and private sector institutions requiring a reliable aromatase inhibitor supply
- Pharmaceutical distributors — B2B partners seeking to fulfill institutional demand for letrozole across the KSA market
As a Bangladeshi-manufactured product, Lenor aligns with procurement frameworks that prioritize verified origin and supply chain transparency. We do not source or distribute Indian-manufactured brands or products originating outside Bangladesh.
Qualified institutional buyers, hospital pharmacies, and licensed distributors in Saudi Arabia are invited to submit availability and procurement inquiries through our contact form. Our team is available to support tender documentation, product specifications, and supply planning for oncology formulary requirements. For additional context on oncology pharmaceutical access, visit our article on supporting cancer patients through pharmaceutical access.
Frequently Asked Questions
What is letrozole used for?
Letrozole is used for the treatment of hormone receptor positive breast cancer in postmenopausal women, covering three approved indications: adjuvant treatment of early breast cancer, extended adjuvant therapy following prior tamoxifen use, and first- or second-line treatment of advanced breast cancer. All prescribing decisions should be made by the treating physician in accordance with official prescribing information and applicable clinical guidelines.
What is the most common side effect of letrozole?
Hot flashes are among the most frequently reported side effects of letrozole, alongside arthralgia, bone pain, hypercholesterolemia, nausea, and alopecia, all consistent with the drug’s mechanism of systemic estrogen suppression. Patients and clinical teams should be aware of the full side effect profile and ensure appropriate monitoring pathways are in place.
Is letrozole relevant for fertility treatment?
Letrozole as supplied under the Lenor brand is indicated exclusively for hormone receptor positive breast cancer in postmenopausal women, and its approved indications do not include fertility treatment. Any questions about off-label uses should be directed to the treating physician.
What monitoring is required during letrozole therapy?
Patients receiving letrozole should undergo bone density monitoring due to the effects of long-term estrogen suppression on skeletal health, as well as serum cholesterol monitoring given the risk of hypercholesterolemia. Patients should also be advised to exercise caution when driving or operating machinery, as fatigue, dizziness, and somnolence have been reported.
How can our institution procure Lenor (letrozole) for our oncology formulary in Saudi Arabia?
Qualified hospital pharmacies, oncology treatment centers, and licensed distributors in the Kingdom of Saudi Arabia are invited to submit procurement inquiries through our contact form, and our team can support tender documentation, product specifications, and supply planning. Lenor 2.5 mg tablets are a Bangladeshi-manufactured product supplied through our network, and we do not source or distribute Indian-manufactured brands or products originating outside Bangladesh.
What should procurement teams verify before including a letrozole product in a KSA formulary?
Institutional buyers should verify the current SFDA registration status of any letrozole product under consideration, as imported pharmaceutical products in the Kingdom of Saudi Arabia are subject to Saudi Food and Drug Authority oversight and must meet applicable registration and importation requirements. Our team is available to assist with the relevant documentation and supply chain transparency information required for formulary submissions.
- 1. FDA Letrozole Prescribing Information (2010)
- 2. FDA Letrozole Prescribing Information (2014)
- 3. FDA Letrozole Prescribing Information (2007)
- 4. FDA Letrozole Prescribing Information (2001)
- 5. DrugBank — Letrozole Monograph (DB01006)
Access This Medicine Through Orio Pharma
We are a specialist oncology medicine supplier delivering to patients, pharmacies, hospitals, and distributors worldwide. Contact us for availability and sourcing support.
We do not publish prices online. All pricing is provided directly by our specialist supply team on request.
Medical Information Notice: This content is for informational purposes only and is based on official pharmaceutical product documentation. It does not constitute medical advice. Patients should consult their doctor or pharmacist before taking any medication.
Regulatory Disclaimer: Sourcing and distribution are subject to regional import regulations, quotas, and verified medical prescriptions where applicable. Pricing and availability are subject to change without notice.
Content Currency: This article was last reviewed and updated in June 2026. Regulatory approval statuses and product availability are subject to change; readers are advised to consult official regulatory databases for the most current information.